- UroToday Home
- Urologic Oncology
The Latest Research on CRPC with Bone Metastases
Recent Abstracts
-
Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer.CRPC w/ bone metastasesMay 22, 2024
-
Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer.CRPC w/ bone metastasesFebruary 16, 2024
-
BeTTer Outcomes Workgroup Health Quality Initiative to optimize bone health for prostate cancer patients in the British Columbia Cancer System.CRPC w/ bone metastasesOctober 30, 2023
-
Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study.CRPC w/ bone metastasesOctober 26, 2023
-
Radium-223 in metastatic castration resistant prostate cancer: whole body diffusion-weighted MRI to assess response.CRPC w/ bone metastasesOctober 9, 2023
-
Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer.CRPC w/ bone metastasesAugust 14, 2023
-
Impact of timing of radium‑223 administration on the survival of patients with bone metastatic castration‑resistant prostate cancer.CRPC w/ bone metastasesAugust 3, 2023
-
Bone scan index (BSI) scoring by using bone scintigraphy and circulating tumor cells (CTCs): predictive factors for enzalutamide effectiveness in patients with castration-resistant prostate cancer and bone metastases.CRPC w/ bone metastasesJune 1, 2023
-
Quantitative assessment of 99mTc-methylene diphosphonate bone SPECT/CT for assessing bone metastatic burden and its prognostic value in patients with castration-resistant prostate cancers: initial results in a single-center retrospective study.CRPC w/ bone metastasesMarch 27, 2023
-
A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL).CRPC w/ bone metastasesMarch 8, 2023
Beyond the Abstracts
-
Bone Targeted Therapy and Skeletal Related Events in the Era of Enzalutamide and Abiraterone Acetate for Castration Resistant Prostate Cancer with Bone Metastases - Beyond the AbstractCRPC w/ bone metastasesOctober 27, 2020
-
Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT: Beyond the AbstractCRPC w/ bone metastasesApril 7, 2017
-
Prostate Cancer Cure is Possible: Beyond the AbstractCRPC w/ bone metastasesJanuary 5, 2017
-
The use of radium 223 dichloride in a multidisciplinary approach for treating metastatic castration-resistant prostate cancer, "Beyond the Abstract," by Elisa BorsòCRPC w/ bone metastasesFebruary 11, 2015